Grace Therapeutics (GRCE) Goodwill & Intangibles (2017 - 2026)

Grace Therapeutics has reported Goodwill & Intangibles for 10 years, with the latest figure at $49.3 million in Q1 2026.

• Quarterly Goodwill & Intangibles changed 0.0% year-over-year to $49.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.3 million (changed 0.0% YoY) and the FY2026 annual result came in at $49.3 million, changed 0.0% from the prior year.
• Goodwill & Intangibles steadied at $49.3 million in Q1 2026 per GRCE's latest filing, from $49.3 million in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $82.8 million in Q1 2022 and troughed at $12.5 million in Q1 2023.
• A 5-year average of $50.3 million and a median of $49.3 million in 2023 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2023 and 2025: Goodwill & Intangibles sank 84.93% in 2023, then soared 294.92% in 2025.
• Over 5 years, Goodwill & Intangibles stood at $82.8 million in 2022, then tumbled by 40.48% to $49.3 million in 2023, then changed by 0.0% to $49.3 million in 2024, then changed by 0.0% to $49.3 million in 2025, then changed by 0.0% to $49.3 million in 2026.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $49.3 million, $49.3 million, and $49.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.